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Background: Diabetes is common in patients with rheumatoid arthritis (RA). Interleukin (IL)-6 is implicated in both
the pathogenesis of RA and in glucose homeostasis; this post hoc analysis investigated the effects of IL-6 receptor
vs. tumour necrosis factor inhibition on glycosylated haemoglobin (HbA1c) in patients with RA with or without diabetes.
Methods: Data were from two placebo-controlled phase III studies of subcutaneous sarilumab 150/200mg q2w +
methotrexate or conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and a phase III monotherapy
study of sarilumab 200mg q2w vs. adalimumab 40mg q2w. Patients with diabetes were identified by medical history or
use of antidiabetic medication (patients with HbA1c ≥ 9% were excluded from all three studies). HbA1c was measured at
baseline and weeks 12/24. Safety and efficacy were assessed in RA patients with or without diabetes.
Results: Patients with diabetes (n= 184) were older, weighed more and exhibited higher RA disease activity than patients
without diabetes (n = 1928). Regardless of diabetes status, in patients on background csDMARDs, least squares (LS) mean
difference (95% CI) in change from baseline in HbA1c for sarilumab 150mg/200mg vs. placebo at week 24 was − 0.28
(− 0.40, − 0.16; nominal p < 0.0001) and − 0.42 (− 0.54, − 0.31; nominal p < 0.0001), respectively. Without csDMARDs, LS
mean difference for sarilumab 200mg vs. adalimumab 40mg at week 24 was − 0.13 (− 0.22, − 0.04; nominal p= 0.0043).
Greater reduction in HbA1c than placebo or adalimumab was observed at week 24 with sarilumab in patients with
diabetes and/or baseline HbA1c ≥ 7%. There was no correlation between baseline/change from baseline in HbA1c and
baseline/change from baseline in C-reactive protein, 28-joint Disease Activity Score, or haemoglobin, nor between HbA1c
change from baseline and baseline glucocorticoid use. Medical history of diabetes or use of diabetes treatments had
limited impact on safety and efficacy of sarilumab and was consistent with overall phase III findings in patients with RA.
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Conclusions: In post hoc analyses, sarilumab was associated with a greater reduction in HbA1c than csDMARDs or
adalimumab, independent of sarilumab anti-inflammatory effects. Prospective studies are required to further assess these
preliminary findings.
Trial registration: ClinTrials.gov NCT01061736: date of registration February 03, 2010; ClinTrials.gov NCT01709578: date of
registration October 18, 2012; ClinTrials.gov NCT02332590: date of registration January 07, 2015.
Keywords: Rheumatoid arthritis, Sarilumab, Adalimumab, Glycosylated haemoglobin, IL-6, Inflammation, Immuno-
metabolismIntroduction
The incidence of type 2 diabetes (T2D) is higher in pa-
tients with RA (17–20% [1–3]) than in the general popu-
lation (8% [4]), independent of glucocorticoid use.
Patients with RA also have increased insulin resistance
compared with individuals without RA [3, 5]. RA disease
outcomes are poorer in patients with comorbid diabetes,
who are also at increased risk for cardiovascular disease
relative to patients who have either RA or diabetes only
[1, 2].
Chronic systemic inflammation is implicated in the
pathogenesis of both RA and diabetes [6]. The pro-
inflammatory cytokines interleukin (IL)-6, tumour ne-
crosis factor-α (TNFα) and IL-1β play key roles in the
synovial inflammation and joint damage associated with
RA and also have systemic effects on extra-articular tis-
sues [7–9]. IL-6 can signal through both membrane-
bound (cis-signalling) and soluble (trans-signalling) IL-6
receptors (IL-6Rs) and therefore has pleiotropic effects
on immune/inflammatory and other cell types, such as
pancreatic β cells, skeletal muscle, adipose tissue and
liver [10, 11]. Chronically elevated levels of systemic IL-6
have been associated with dysfunctional glucose metab-
olism and homeostasis and with the induction of insulin
resistance in liver and adipose tissue [11–13]. Elevated
levels of IL-6 are an independent risk factor for T2D
[13–15], and IL-6 alone or in combination with IL-1β
inhibits β cell function [16, 17]. Similarly, effects on glu-
cose metabolism, insulin resistance, pancreatic β cell
function and risk of diabetes are attributed to elevations
in TNFα and IL-1β [6, 15, 18, 19], whilst IL-1β antagon-
ism reduces hyperglycaemia and improves pancreatic
β cell function in patients with T2D [20, 21]. Of note,
the metabolic effect size of IL-1β antagonism is consid-
erably greater in patients with RA and comorbid T2D
[21], indicating that the efficacy of anticytokine biologics
correlates with the inflammatory burden.
Medical management of T2D and RA can be compli-
cated by the potential effects of RA treatments on glu-
cose levels. Oral glucocorticoids increase the risk for
diabetes in patients with RA [22, 23] because of the ad-
verse metabolic actions of these drugs, with higher dose
and longer treatment duration increasing the risk [23].By contrast, the anti-inflammatory drug hydroxychloro-
quine reduced the risk of incident diabetes in patients
with RA [24, 25] and was also associated with a
favourable effect on glycaemia in patients with RA in the
absence of diabetes [26]. These effects are not necessar-
ily associated with direct actions on insulin resistance
and/or pancreatic β cell function [24, 25, 27], but rather
to a reduction of low-grade inflammation by inhibiting
the inflammasome [28]. Methotrexate (MTX) also re-
duces glycosylated haemoglobin (HbA1c) levels and the
risk for diabetes in patients with RA [29], likely inde-
pendently of insulin sensitivity [30].
Because diabetes is a common comorbidity in pa-
tients with RA and cytokines are implicated in glu-
cose homeostasis, we conducted post hoc analyses of
three sarilumab phase III randomised clinical trials.
These analyses aimed to assess the effect of sarilumab
(a human monoclonal antibody that blocks the IL-
6Rα), as monotherapy or in combination with con-
ventional synthetic disease-modifying antirheumatic
drugs (csDMARDs) on HbA1c levels compared with
either placebo (+ MTX/csDMARD) or adalimumab
monotherapy [31–33]. We also assessed the safety




Details of the three phase III study designs have been
described previously [31–33]. In brief, the MOBILITY
trial (NCT01061736) was conducted to investigate the
efficacy and safety of up to 52 weeks of sarilumab (or
placebo) in combination with MTX in patients with
moderate-to-severe active RA and an inadequate re-
sponse to MTX (MTX-IR); this trial is referred to herein
as the MTX-IR sarilumab + MTX study. The TARGET
trial (NCT01709578) was conducted to investigate the
efficacy and safety of up to 24 weeks of sarilumab (or
placebo) in combination with background conventional
synthetic DMARDs (csDMARDs) in patients with
moderate-to-severe RA who were intolerant of, or who had
inadequate response to, TNF inhibitors (TNFi-INT/IR); this
study is referred to herein as the TNFi-INT/IR sarilumab +
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was conducted to compare the 24-week efficacy and safety
of sarilumab monotherapy with adalimumab monotherapy
in biologic DMARD-naïve patients with moderate-to-
severe active RA who were intolerant of, or had an IR to,
MTX (MTX-INT/IR); this study is referred to herein as the
monotherapy study. Patients with uncontrolled diabetes
mellitus (defined by HbA1c ≥ 9% at the screening visit)
were excluded from participation. Patients treated with ≤
10mg oral prednisone or equivalent at a stable dose for at
least 4 weeks prior to the baseline visit were included; how-
ever, changes in dose were not permitted during the
double-blind treatment periods unless required for treat-
ment of an adverse event (AE) (other than worsening RA).
The three protocols were approved by the appropriate
ethics committees/institutional review boards, and each
patient provided written informed consent before par-
ticipation in the study. The studies were conducted in
compliance with institutional review board regulations,
the International Conference on Harmonisation Guide-
lines for Good Clinical Practice and the Declaration of
Helsinki.
For the purposes of these post hoc analyses, patients
were classified as having diabetes if they reported either
a medical history of the disease or baseline use of medi-
cation to treat diabetes (e.g. metformin, sulfonylureas,
dipeptidyl peptidase 4 inhibitors or insulins).
Assessments
HbA1c was measured at baseline in all three studies and
also at weeks 12 and 24 in the TNFi-INT/IR sarilumab +
csDMARD and monotherapy studies. In the MTX-IR
sarilumab + MTX study, HbA1c was assessed after base-
line at the investigators’ discretion.
Safety assessments included the incidence of treatment-
emergent adverse events (TEAEs), serious TEAEs (SAEs),
serious infections and specific abnormalities in laboratory
tests. AEs were described at the Medical Dictionary for
Regulatory Activities (version 16.0) preferred-term level.
Efficacy assessments included the American College of
Rheumatology 20% (ACR20) response rate and the
change from baseline in the Health Assessment
Questionnaire-Disability Index (HAQ-DI), Disease Ac-
tivity Score (28 joints) using C-reactive protein (DAS28-
CRP) and Clinical Disease Activity Index (CDAI) at
week 24.
Statistical methods
The analyses of patients with and without diabetes were
conducted post hoc; therefore, p values should be con-
sidered nominal.
Changes in HbA1c were analysed for subgroups de-
fined by a medical history of diabetes or baseline use of
an antidiabetic medication. To determine whetherchanges in HbA1c might be therapeutically relevant for
patients with marginal glycaemic control, the analyses
were repeated in a subgroup of patients who had a base-
line HbA1c value ≥ 7.0% [34]. To investigate potential
modulators of HbA1c, other than the investigational
treatment, patients were also classified by oral gluco-
corticoid use and type of treatment for diabetes, and
Spearman’s rank correlation coefficients (rS) were calcu-
lated for baseline HbA1c vs. baseline CRP, DAS28-CRP
and haemoglobin and for changes in HbA1c vs. changes
in CRP, DAS28-CRP and haemoglobin.
Values for observed cases were used without imput-
ation for analyses of safety and laboratory parameters.
No formal statistical analysis of AEs was conducted for
patients with RA in the presence vs. absence of diabetes
(comparisons were descriptive).
Efficacy was assessed in the intent-to-treat population.
For efficacy analysis, data from the MTX-IR sarilumab +
MTX study and the TNFi-INT/IR sarilumab +
csDMARD studies were pooled. For categorical efficacy
variables, patients were considered nonresponders from
the time they started rescue therapy or discontinued the
study medication. For continuous efficacy variables, as-
sessments were set to missing from the time a patient
received rescue therapy or discontinued study medica-
tion before the end of the study. Missing values were
not imputed. Changes in efficacy variables were mod-
elled using a repeated-measures-mixed-effect model,
assuming unstructured covariance with treatment, re-
gion, visit, subgroup, treatment-by-visit interaction,
treatment-by-subgroup interaction and treatment-by-
visit-by-subgroup interaction included in the model. A
nominal p value < 0.05 was considered significant.
Results
Patient baseline characteristics and disposition
Across the three phase III studies, 184 of 2112 (8.7%)
patients had a medical history of diabetes or concomi-
tant use of antidiabetic treatment at baseline (MTX-IR
sarilumab + MTX study: n = 91; TNFi-INT/IR sarilumab
+ csDMARDs study: n = 67; monotherapy study: n = 26)
(Table 1). The majority of patients with diabetes in each
study (75–82%) were receiving concomitant antidiabetic
medications at baseline, with noninsulin blood glucose-
lowering medications being the most common (Table 1).
Patients with diabetes were significantly older (56.5
years vs. 51.0 years; p < 0.0001), weighed more (84.1 kg
vs. 74.0 kg; p < 0.0001) and had a significantly higher
body mass index (32.2 kg/m2 vs. 28.0 kg/m2; p < 0.0001)
at baseline than patients without diabetes. Patients with
diabetes also had a significantly higher mean swollen
joint count and tender joint count and greater disability
at baseline than those without diabetes (Table 1). The
proportion of patients with or without diabetes who
Table 1 Baseline characteristics of patients with and without diabetes (medical history of diabetes or concomitant use of
antidiabetic treatment) across three phase III studies
With diabetes (N = 184) Without diabetes (N = 1928) p value
Age (years) < 0.0001
Mean (SD) 56.5 (9.4) 51.0 (12.1)
Sex, n (%) 0.3348
Female 146 (79.3) 1585 (82.2)
Male 38 (20.7) 343 (17.8)
Race, n (%) 0.0907
Caucasian/White 147 (79.9) 1607 (83.4)
Black 8 (4.3) 44 (2.3)
Asian 15 (8.2) 99 (5.1)
Other 14 (7.6) 178 (9.2)
Weight (kg) < 0.0001
Mean (SD) 84.08 (21.59) 74.04 (18.76)
Body mass index (kg/m2) < 0.0001
Mean (SD) 32.18 (7.40) 28.04 (6.38)
Duration of RA since diagnosis (years) 0.6294
Mean (SD) 9.82 (8.81) 9.51 (8.44)
Rheumatoid factor, n (%) 0.0964
Positive 136 (74.3) 1517 (79.5)
Negative 47 (25.7) 390 (20.5)
Anti CCP antibody, n (%) 0.0593
Positive 143 (77.7) 1587 (83.2)
Negative 41 (22.3) 320 (16.8)
Tender joint count (0–68) 0.0017
Mean (SD) 30.97 (15.92) 27.11 (14.11)
Swollen joint count (0–66) 0.0185
Mean (SD) 19.72 (11.90) 17.57 (10.02)
HAQ-DI (0–3) 0.0010
Mean (SD) 1.82 (0.66) 1.66 (0.63)
CRP (mg/L) 0.3210
Mean (SD) 24.90 (29.39) 22.67 (24.22)
Oral glucocorticosteroid use, n (%) 119 (64.7) 1177 (61.0) 0.3344
Mean (SD) prednisone equivalent dose, mg 6.6 (2.63) 6.6 (2.68) 0.7462
Hydroxychloroquine use, n (%) 4 (2.2) 33 (1.7) > 0.9999
Antidiabetic medication use, n (%) 143 (77.7) NR NR
Any noninsulin blood glucose-lowering drug, n (%)a 85 (46.2) NR NR
≥ 2 noninsulin blood glucose-lowering drugs, n (%)b 32 (17.4) NR NR
Any insulin and analogue without oral blood glucose lowering drug, n (%) 13 (7.1) NR NR
Any insulin and analogue plus oral blood glucose lowering drug, n (%) 14 (7.6) NR NR
Percentages are calculated using number of patients assessed as denominator
p values are based on t test for continuous variables and chi-square test if frequency in all cells ≥ 5 and Fisher exact test if frequency in at least one cell < 5, for
categorical variables
CCP cyclic citrullinated peptide, CRP C-reactive protein, HAQ-DI Health Assessment Questionnaire-Disability Index, Number number of patients assessed, NR not
relevant, RA rheumatoid arthritis, SD standard deviation
aExcluding insulins, monotherapy
bExcluding insulins
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equivalent) at baseline was 69.2% and 62.6%, respect-
ively, in the MTX-IR sarilumab + MTX study, 59.7%
and 62.8%, respectively, in the TNFi-INT/IR sarilumab +
csDMARDs study and 65.4% and 53.9%, respectively, in
the monotherapy study.
Rates of study completion were similar between pa-
tients with and without diabetes (Table S1).
Reduction in HbA1c
Patients with RA who were TNFi-INT/IR (irrespective of
diabetic status) and were treated with sarilumab +
csDMARDs exhibited a greater reduction in HbA1c
from baseline to week 24 compared with those treated
with placebo + csDMARDs (Fig. 1a). The least squares
(LS) mean differences (95% CI; nominal P) for sarilumab
150 mg q2w + csDMARD and sarilumab 200 mg q2w +
csDMARDs, respectively, vs. placebo + csDMARDs were
− 0.28 (− 0.40, − 0.16; p < 0.0001) and − 0.42 (− 0.54,
− 0.31; p < 0.0001). In the monotherapy study, patients
with RA who were MTX-INT/IR and treated with sarilu-
mab also exhibited a greater reduction in HbA1c than
those treated with adalimumab (Fig. 1b). Notably, the LS
mean difference (95% CI; nominal p) for sarilumab 200mg
q2w from adalimumab 40mg q2w at week 24 was − 0.13
(− 0.22, − 0.04; p = 0.0043). In all three studies, reductions
in HbAc1 with sarilumab occurred in patients who
achieved disease activity thresholds of DAS28-CRP < 2.6 or
< 3.2 (low disease activity) as well as in patients who did
not achieve disease activity thresholds (Table S2).
For patients with a medical history of diabetes or treat-
ment for diabetes, the reduction in HbA1c at week 24
(Fig. 1c, d) was greater with sarilumab + csDMARDs (LS
mean difference, − 0.67 [− 0.98, − 0.37; p < 0.0001] and −
0.47 [− 0.77, − 0.17; p = 0.0021] for the sarilumab 200mg
q2w group and 150 mg q2w group, respectively) than for
patients treated with placebo + csDMARDs. In the
monotherapy study, the reduction in HbA1c was greater
with sarilumab 200 mg q2w than with adalimumab
40 mg q2w (LS mean difference, − 0.43 [− 0.80, −
0.05; p = 0.0257]).
Among patients with baseline HbA1c greater than the
target of 7.0%, those who received sarilumab +
csDMARDs had a greater reduction from baseline in
HbA1c at week 24 compared with those who received
placebo + csDMARDs (p = 0.0097; p = 0.0003). A similar
result was seen in those who received sarilumab com-
pared with adalimumab monotherapy (p = 0.0002;
Table 2).
Baseline HbA1c values did not correlate with baseline
CRP, DAS28-CRP or haemoglobin levels in the overall
study population in any of the three studies (all rS < 0.1),
even when patients with a baseline HbA1c value ≥ 7%
were included. There was no interaction between thereduction in HbA1c levels at week 12 or 24 and baseline
glucocorticoid use or the increase in haemoglobin levels
in patients with RA in the absence or presence of dia-
betes (Table S3). In the TNFi-INT/IR sarilumab +
csDMARDs study, changes in HbA1c at week 12 or 24
did not correlate with change in CRP (all rS < 0.16),
DAS28-CRP (all rS < 0.1) or haemoglobin (all rS < 0.1). In
the monotherapy study, a weak positive correlation
(rS < 0.24) was observed between changes in HbA1c and
changes in CRP at week 24 in both the sarilumab
200 mg q2w (rS 0.236; p = 0.003) and adalimumab 40mg
q2w groups (rS 0.174; p = 0.035) and the change in
HbA1c and DAS28-CRP in the adalimumab group
(0.188; p = 0.023). In patients who received sarilumab +
csDMARDs or sarilumab monotherapy, changes in
HbA1c at week 24 were similar whether or not increases
in haemoglobin levels were observed at week 12 (data
not shown) and week 24 (Table S3). Similar results were
observed in models adjusted for various measures of dis-
ease activity (Table S4).
Rheumatoid arthritis disease activity efficacy outcomes
Efficacy outcomes at week 24 for ACR20 and change
from baseline in HAQ-DI, DAS28-CRP and CDAI
are shown in Fig. S1. In the pooled analysis of the
two placebo-controlled studies of sarilumab + MTX/
csDMARDs, treatment by diabetes status interaction
tests were not significant for ACR20 (p = 0.224) or
for change from baseline in HAQ-DI (p = 0.475),
DAS28-CRP (p = 0.110) or CDAI (p = 0.597). In the
monotherapy trial, the small number of patients with
diabetes limited data interpretation; however, treat-
ment by subgroup interaction test results were not
significant for ACR20 (p = 0.585) or for change from
baseline in HAQ-DI (p = 0.719) but were significant
for change from baseline in DAS28-CRP (p = 0.003)
and CDAI (p = 0.025).
Safety
The rates of treatment-emergent SAEs and TEAEs lead-
ing to death or treatment discontinuation during the
double-blind treatment phase in the three studies are
shown for patients with or without diabetes in Table 3.
In the placebo-controlled studies, the overall TEAE rate
for most treatment groups was numerically higher in pa-
tients with diabetes compared with those without dia-
betes (with sarilumab 200 mg + MTX: 97.3% vs. 76.9%;
placebo + MTX: 74.1% vs. 61.1%; with sarilumab 200 mg
+ csDMARDs: 61.9% vs. 65.6%; and with placebo +
csDMARDs: 73.9% vs. 46.2%). Of note, in the monother-
apy trial, TEAE rates were similar for patients treated
with sarilumab vs. adalimumab, and within treatment
groups the TEAE rate was numerically higher for pa-
tients with diabetes than for those without (sarilumab:
Fig. 1 Change in HbA1c in patients with RA (irrespective of diabetes
status) treated with a sarilumab 150/200mg q2w + csDMARDs or
placebo + csDMARDs and b sarilumab 200mg q2w or adalimumab
40mg q2w. Change in HbA1c in patients with RA and diabetes
treated with c sarilumab 150/200mg q2w + csDMARDs or placebo
+ csDMARDs and d sarilumab 200mg q2w or adalimumab 40 mg
q2w. p values are nominal. csDMARD, conventional disease-
modifying antirheumatic drug; HbA1c, glycosylated haemoglobin; LS,
least squares; PBO, placebo; q2w, every 2 weeks; RA, rheumatoid
arthritis; SE, standard error
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ively; Table 3). However, the total number of patients
with diabetes in each treatment group in the monother-
apy trial was low compared with the number of patients
without diabetes (Table 3), which limited comparisons.
Rates of infection were higher in patients with diabetes
than without diabetes for all treatment groups, except
for patients who were TNFi-INT/IR treated with sarilu-
mab 200 mg q2w + csDMARDs (Table 4). The rate of
serious infections, opportunistic infections and infections
leading to treatment discontinuation was low and com-
parable in patients with or without diabetes who were
treated with sarilumab. There were no cases of tubercu-
losis among patients with diabetes; one case of tubercu-
losis was reported in a patient without diabetes who
received adalimumab monotherapy (Table 4).
The overall incidence of hypersensitivity reactions was
numerically greater among patients with diabetes
(Table 4); however, no patients with diabetes experi-
enced serious hypersensitivity reactions. Two patients
without diabetes who were treated with sarilumab +
csDMARDs (n = 1) or adalimumab monotherapy (n = 1)
experienced serious hypersensitivity reactions. Regarding
hypersensitivity reactions leading to treatment discon-
tinuation: these were reported in two patients with dia-
betes who were treated with sarilumab 200mg +
csDMARD (n = 1) or monotherapy (n = 1) and five pa-
tients without diabetes who were treated with sarilumab
150 mg q2w + MTX (n = 3), sarilumab 200 mg q2w +
MTX (n = 1) or sarilumab 200 mg q2w + csDMARDs
(n = 1).
The incidence of selected laboratory abnormalities is
shown in Table 4. No spontaneously reported symptom-
atic or biochemical hypoglycaemia TEAEs were reported
in any of the three studies. A reduced absolute neutro-
phil count (ANC) was generally seen more frequently in
patients without diabetes across all studies. Platelet
counts < 50 G/L were uncommon in both groups and
not observed in the 184 patients with diabetes. Alanine
aminotransferase elevations were not increased in
patients with diabetes compared with those without dia-
betes. The proportions of patients with shifts from base-
line to highest post-baseline cholesterol (≥ 6.2 mmol/L
[≥ 239.7 mg/dL]), low-density lipoprotein cholesterol
Table 2 Change from baseline at week 24 in HbA1c in patients with RA and subgroups of patients with RA and diabetes from
phase III studies of sarilumab + csDMARDs or sarilumab monotherapy
Combination therapy with csDMARDs in TNFi-INT/IR patients Monotherapy in MTX-INT/IR patients










Patients with a medical history of diabetes or baseline use of antidiabetic medication
Number 15 16 15 14 6
Baseline mean (SD) 7.20 (1.06) 6.94 (1.08) 6.96 (1.09) 6.77 (0.89) 6.65 (1.17)
LS mean change (SE)a 0.23 (0.11) − 0.24 (0.11) − 0.44 (0.11) 0.15 (0.11) − 0.28 (0.16)
LS mean difference, 95% CIa − 0.47 (− 0.77, − 0.17) − 0.67 (− 0.98, − 0.37) − 0.43 (− 0.80, − 0.05)
p value vs. placebo/adalimumaba 0.0021 < 0.0001 0.0257
Baseline HbA1c ≥ 7.0%
Number 11 10 9 6 4
Baseline mean (SD) 7.80 (0.58) 7.77 (0.59) 7.88 (0.61) 7.57 (0.49) 7.78 (0.54)
LS mean change (SE)a − 0.08 (0.13) − 0.56 (0.13) − 0.77 (0.14) 0.29 (0.16) − 0.67 (0.20)
LS mean diff, 95% CIa − 0.48 (− 0.84, − 0.12) − 0.69 (− 1.06, − 0.32) − 0.96 (− 1.46, − 0.46)
p value vs. placebo/adalimumaba 0.0097 0.0003 0.0002
All assessments are set to missing from the time a patient prematurely discontinues study medication
CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, HbA1c glycosylated haemoglobin, INT intolerant, IR inadequate
response, LS least squares, MMRM mixed-effect model repeat measurement, MTX methotrexate, Number number of patients with assessment at both baseline and
week 24, q2w every 2 weeks, SD standard deviation, SE standard error, TNFi tumour necrosis factor-α inhibitor
aMMRM assuming an unstructured covariance structure. Model = subgroup, treatment, region, visit, treatment-by-visit interaction, treatment-by-subgroup
interaction and treatment-by-visit-by-subgroup interaction. Nominal p values for differences between sarilumab and comparator
Table 3 Overview of TEAEs during the double-blind treatment phases of phase III trials
Combination therapy with MTX in
MTX-IR patients
Combination therapy with
csDMARDs in TNFi-INT/IR patients
Monotherapy in MTX-INT/
IR patients


























































































TEAE leading to death, n/N (%)
With diabetes 1/27
(3.7)























































csDMARD conventional synthetic disease-modifying antirheumatic drug, INT intolerant, IR inadequate response, MTX methotrexate, q2w every 2 weeks, SAE serious
TEAE, TEAE treatment-emergent adverse event, TNFi tumour necrosis factor-α inhibitor
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Table 4 Selected treatment-emergent adverse events
Combination therapy with MTX in
MTX-IR patients
52 weeks





















Patients with ≥ 1 infection, n/N (%)
With diabetes 12/27 (44.4) 12/27 (44.4) 20/37 (54.1) 8/23 (34.8) 10/23 (43.5) 4/21 (19.0) 9/16 (56.3) 3/10 (30.0) 78/184 (42.4)
Without diabetes 115/370 (31.1) 156/374 (41.7) 139/359 (38.7) 40/158 (25.3) 30/158 (19.0) 52/163 (31.9) 42/168 (25.0) 50/174 (28.7) 624/1924 (32.4)
Patients with ≥ 1 serious infection, n/N (%)
With diabetes 4/27 (14.8) 1/27 (3.7) 1/37 (2.7) 0/23 1/23 (4.3) 0/21 0/16 0/10 7/184 (3.8)
Without diabetes 6/370 (1.6) 10/374 (2.7) 14/359 (3.9) 2/158 (1.3) 0/158 2/163 (1.2) 2/168 (1.2) 2/174 (1.1) 38/1924 (2.0)
Patients with infection leading to treatment discontinuation, n/N (%)
With diabetes 1/27 (3.7) 0/27 0/37 0/23 3/23 (13.0) 0/21 0/16 0/10 4/184 (2.2)
Without diabetes 5/370 (1.4) 13/374 (3.5) 11/359 (3.1) 1/158 (0.6) 2/158 (1.3) 5/163 (3.1) 2/168 (1.2) 1/174 (0.6) 40/1924 (2.1)
Patients with opportunistic infections (including tuberculosis), n/N (%)
With diabetes 0/27 0/27 1/37 (2.7) 0/23 0/23 0/21 0/16 0/10 1/184 (0.5)
Without diabetes 2/370 (0.5) 2/374 (0.5) 3/359 (0.8) 1/158 (0.6) 0/158 2/163 (1.2) 1/168 (0.6) 1/174 (0.6) 12/1924 (0.6)
Patients with tuberculosis, n/N (%)
With diabetes 0/27 0/27 0/37 0/23 0/23 0/21 0/16 0/10 0/184
Without diabetes 0/370 0/374 0/359 0/158 0/158 0/163 1/168 (0.6) 0/174 1/1924 (0.1)
Patients with ≥ 1 hypersensitivity, n/N (%)
With diabetes 1/27 (3.7) 1/27 (3.7) 3/37 (8.1) 2/23 (8.7) 3/23 (13.0) 4/21 (19.0) 0/16 2/10 (20.0) 16/184 (8.7)
Without diabetes 17/370 (4.6) 25/374 (6.7) 26/359 (7.2) 5/158 (3.2) 7/158 (4.4) 7/163 (4.3) 10/168 (6.0) 8/174 (4.6) 105/1924 (5.5)
Patients with ≥ 1 serious hypersensitivity, n/N (%)
With diabetes 0/27 0/27 0/37 0/23 0/23 0/21 0/16 0/10 0/184
Without diabetes 0/370 0/374 1/359 (0.3) 0/158 0/158 0/163 1/168 (0.6) 0/174 2/1924 (0.1)
Patients with ≥ 1 hypersensitivity leading to treatment discontinuation, n/N (%)
With diabetes 0/27 0/27 1/37 (2.7) 0/23 0/23 0/21 0/16 1/10 (10.0) 2/184 (1.1)
Without diabetes 1/370 (0.3) 3/374 (0.8) 1/359 (0.3) 0/158 0/158 1/163 (0.6) 1/168 (0.6) 0/174 7/1924 (0.4)
ANC < 1.5 G/L (non-black patients) or < 1.0 G/L (black patients), n/N (%)
With diabetes 1/27 (3.7) 1/27 (3.7) 5/37 (13.5) 0/23 1/23 (4.3) 5/21 (23.8) 1/16 (6.3) 3/10 (30.0) 17/184 (9.2)
Without diabetes 5/370 (1.4) 72/374 (19.3) 88/359 (24.5) 2/158 (1.3) 30/158 (19.0) 37/162 (22.8) 39/167 (23.4) 59/174 (33.9) 332/1922 (17.3)
Platelets < 50 G/L, n/N (%)
With diabetes 0/27 0/27 0/37 0/23 0/23 0/21 0/16 0/10 0/184
Without diabetes 0/370 0/374 2/358 (0.6) 0/158 0/158 1/162 (0.6) 0/0 1/174 (0.6) 4/1921 (0.2)
Total cholesterol baseline normal/missing to post baseline ≥ 6.2mmol/L, n/N (%)
With diabetes 6/25 (24.0) 2/23 (8.7) 12/30 (40.0) 6/19 (31.6) 9/23 (39.1) 7/20 (35.0) 2/15 (13.3) 2/7 (28.6) 46/162 (28.4)
Without diabetes 62/325 (19.1) 128/327 (39.1) 140/315 (44.4) 18/140 (12.9) 51/130 (39.2) 52/141 (36.9) 35/131 (26.7) 53/140 (37.9) 539/1649 (32.7)
Total LDL-C baseline normal/missing to post-baseline LDL-C ≥ 4.1mmol/L, n/N (%)
With diabetes 2/25 (8.0) 3/25 (12.0) 11/32 (34.4) 4/21 (19.0) 7/22 (31.8) 5/20 (25.0) 1/15 (6.7) 2/9 (22.2) 35/169 (20.7)
Without diabetes 41/344 (11.9) 82/342 (24.0) 101/334 (30.2) 10/148 (6.8) 39/146 (26.7) 38/151 (25.2) 28/142 (19.7) 40/153 (26.1) 379/1760 (21.5)
Total triglycerides baseline normal/missing to post-baseline ≥ 4.6mmol/L, n/N (%)
With diabetes 2/27 (7.4) 0/0 3/36 (8.3) 0/23 1/23 (4.3) 0/21 1/16 (6.3) 1/10 (10.0) 8/181 (4.4)
Without diabetes 1/368 (0.3) 11/372 (3.0) 13/358 (3.6) 1/157 (0.6) 5/153 (3.3) 6/161 (3.7) 4/164 (2.4) 3/173 (1.7) 44/1906 (2.3)
ALT > 3 to ≤ 5 ULN, n/N (%)
With diabetes 0/27 0/27 6/37 (16.2) 0/23 0/23 0/21 2/16 (12.5) 0/10 8/184 (4.3)
Without diabetes 9/370 (2.4) 33/374 (8.8) 25/359 (7.0) 2/158 (1.3) 4/157 (2.5) 7/161 (4.3) 10/167 (6.0) 11/174 (6.3) 101/1920 (5.3)
ALT > 5 to ≤ 10 ULN, n/N (%)
With diabetes 0/27 0/27 2/37 (5.4) 0/23 0/23 0/21 1/16 (6.3) 0/10 3/184 (1.6)
Without diabetes 1/370 (0.3) 11/374 (2.9) 8/359 (2.2) 0/158 0/158 0/161 2/167 (1.2) 3/174 (1.7) 25/1920 (1.3)
ALT alanine aminotransferase, ANC absolute neutrophil count, csDMARD conventional synthetic disease-modifying antirheumatic drug, INT intolerant, IR inadequate response,
LDL-C low-density lipoprotein cholesterol, MTX methotrexate, q2w every 2 weeks, TNFi tumour necrosis factor α inhibitor, ULN upper limit of normal
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mmol/L [≥ 407.1 mg/dL]) were not consistently higher in
patients with diabetes compared with those without
diabetes (Table 4).
There were no interactions between diabetes status
and incidence of weight gain > 5%. Among patients
treated with sarilumab 200 mg q2w, the percentages of
patients with > 5% weight gain at week 24 with and
without diabetes were 17.2% vs. 18.4%, 13.3% vs. 18.3%
and 14.3% vs. 11.9% for patients treated with sarilumab
+ MTX, sarilumab + csDMARDs or sarilumab mono-
therapy, respectively (Table S5).
Discussion
Diabetes is a common comorbid condition among pa-
tients with RA [1, 2, 35]. Medical management of both
conditions can be complicated, because RA disease ac-
tivity and the use of glucocorticoids, csDMARDs and
bDMARDs (often in combination) to treat RA may
affect glucose levels through their effects on glucose me-
tabolism, insulin sensitivity and pancreatic β cell func-
tion [3, 24, 25, 36].
These post hoc analyses of three phase III clinical
studies in patients with RA show that sarilumab as
monotherapy or in combination with MTX/csDMARDs
is associated with a greater reduction in HbA1c than ada-
limumab monotherapy or placebo + MTX/csDMARDs,
particularly in patients with diabetes. Reductions in
HbA1c were more prominent in patients treated with sari-
lumab compared with either MTX/csDMARDs or adali-
mumab in patients whose baseline HbA1c was ≥ 7%, a
level that exceeds the target HbA1c of < 7% recommended
by the American Diabetes Association, supporting the
possibility of improving, as well as maintaining, glucose
homeostasis.
It is well recognised that oral glucocorticoids, in
addition to immune-suppressive actions, also affect glu-
cose homeostasis. In RA, oral glucocorticoids are com-
monly used and it is important to notice that the effects
of sarilumab on HbA1c were not attenuated by con-
comitant glucocorticoid treatment (≤ 10 mg prednisone
equivalent). In addition, the observed reduction in
HbA1c could not be explained by the expected increase
in haemoglobin associated with IL-6R blockade, which
indicates that its effect on HbA1c did not reflect an in-
direct effect of a change in haemoglobin levels. Whilst
the current analyses cannot exclude the general influ-
ence of systemic inflammation as a cause of changes in
glycaemia, a correlation between changes in HbA1c and
changes in CRP was not observed in the TNFi-INT/IR
sarilumab + csDMARDs study and correlations were
minimal when sarilumab was used as monotherapy
(Spearman’s rank correlations < 0.24). Similar results
were observed with three models incorporating differentmeasures of change in disease activity and inflammation
(CRP and CDAI; DAS28-CRP; and tender and swollen
28 joint counts, patient and physician global assess-
ments, and CRP). These results support an effect of sari-
lumab in reducing HbA1c that is independent of anti-
inflammatory effects, although some degree of associ-
ation between general effects on inflammation and
changes in glycaemia cannot be ruled out.
These analyses also showed that sarilumab + MTX/
csDMARDs or as monotherapy is efficacious in patients
with or without diabetes; this is consistent with the over-
all efficacy findings from all three phase III studies [31–
33]. Furthermore, there were no major differences in the
safety profile of sarilumab in patients with RA in the
presence or absence of diabetes, although patients with
uncontrolled diabetes and therefore potentially greater
risk were excluded from these studies. These findings
are reassuring given the possible vulnerabilities associ-
ated with diabetes (e.g. patients with poor glycaemic
control have greater susceptibility to developing infec-
tions, especially if they are older or more likely to be re-
ceiving oral glucocorticoids [37]). In this analysis, the
rate of serious infections, opportunistic infections and
infections leading to treatment discontinuation was simi-
lar in patients with or without diabetes, despite a numer-
ically higher rate of decreased ANC in patients with
diabetes. Patients with treated diabetes are also at risk
for hypoglycaemia, especially those whose treatment in-
cludes insulin or an insulin secretagogue [38]. There
were no reports of symptomatic or biochemical
hypoglycaemia in any of the studies, even though ap-
proximately 17% of the patients with diabetes were tak-
ing ≥ 2 noninsulin blood glucose-lowering medications
and approximately 8% were using insulin or an insulin
secretagogue. Modelling to assess the effect of concomi-
tant use of hydroxychloroquine, known to induce symp-
tomatic hypoglycaemia, by diabetic status showed no
significant interaction at week 12 or 24 (data not
shown). Changes in lipid parameters were generally
comparable in the presence or absence of diabetes, and
no interaction between diabetes and weight gain was ob-
served. This finding may be particularly important, given
the association between RA and comorbid diabetes and
cardiovascular risk [39].
These analyses have some notable limitations: they
were conducted post hoc; and none of the studies in-
cluded were designed specifically to evaluate HbA1c
levels. The patients who had diabetes were selected on
the basis of previous clinical history or current antidia-
betic medication use, and patients with uncontrolled dia-
betes, defined as HbA1c ≥ 9.0%, were excluded. Whilst
this exclusion is standard in trials, it does introduce a
bias in the study population when compared with the
general population. In addition, diet and exercise were
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were no specific recommendations to maintain dietary
or exercise habits in the individual study protocols. In
the monotherapy study, the number of patients with dia-
betes in the two treatment groups was small. The pro-
portion of non-white patients, in whom the prevalence
of diabetes may differ, was low in the pooled studies. No
analyses were performed to investigate any differences
between such populations. Despite these limitations,
findings across the three studies were consistent.
Although the analyses were conducted post hoc, data
were collected in a prospective and blinded manner, and
blood samples were analysed by a central laboratory, re-
ducing assay variability. Although the numbers of dia-
betic patients in the sarilumab studies were small, they
were larger than those reporting reductions in HbA1c in
previous studies of tocilizumab, in which patients were
treated openly (n = 10 [40] and n = 34 [41]) or only eval-
uated HbA1c after 104 weeks [42]. In none of the afore-
mentioned tocilizumab studies nor during the course of
randomised, well-controlled, multinational studies de-
signed to support marketing authorisation of a therapy
for RA was HbA1c collected, nor were patients as thor-
oughly characterised with respect to concomitant gluco-
corticoid use, treatment for diabetes, or safety of the
treatments. Other studies of the effects of IL-6 receptor
blockade on insulin sensitivity/resistance in patients with
RA excluded patients with diabetes [24, 43].
Although chronic inflammation has long been impli-
cated as a mediator of insulin resistance and β cell fail-
ure in patients with diabetes, the literature provides no
clear guidance on the use of bDMARDs in patients with
RA comorbid with diabetes. Studies of acute cytokine in-
fusion on glucose metabolism in healthy volunteers may
be inappropriate models for chronic inflammatory dis-
ease, given that they have produced contradictory re-
sults: acute infusion of human recombinant IL-6 has
resulted in both an increase in fasting glucose concen-
trations [44] and a decrease in postprandial glucose con-
centrations with increased insulin sensitivity [45].
To date, the impact of TNFi on HbA1c, insulin sensi-
tivity/resistance or pancreatic β cell function is unclear
[46–52]. An infusion of human recombinant TNFα has
been shown to increase [53], as well as decrease [54], in-
sulin sensitivity in healthy volunteers. Symptomatic
hypoglycaemia has been reported in patients with dia-
betes and RA or psoriasis who were treated with etaner-
cept [55–58]. Properly designed clinical trials testing the
effect of biologic anti-inflammatory drugs inhibiting
TNF (e.g. CDP-571, etanercept) are lacking.
The evidence for IL-1 signalling involvement in glu-
cose regulation is more supportive. A recent meta-
analysis of > 2900 patients T2D treated with biologics
that block IL-1 signalling (anakinra, canakinumab,gevokizumab, LY2189102) demonstrated a significant
overall reduction in HbA1c of 0.32%; this included a
study of patients with RA and T2D that showed a re-
duction of > 0.8% [21].
However, no bDMARD has yet been recommended or
approved for the treatment of diabetes, although a clin-
ical trial to assess the potential efficacy of anti-IL-6 ther-
apy (tocilizumab) in patients with type 1 diabetes is in
progress [59]. A better understanding of the potential
differences in the effect of IL-6R blockade vs. IL-1β/TNFα
antagonism on common comorbidities in RA should lead
to more informed and individually tailored choices in RA
disease management.Conclusions
In a post hoc analysis of three studies, IL-6R inhibition
with sarilumab was associated with a reduction in
HbA1c in patients with RA with and without comorbid
diabetes that were greater than with placebo or adalimu-
mab and could not be attributed solely to changes in
CRP, disease activity or haemoglobin. The safety and ef-
ficacy of sarilumab in patients with diabetes were con-
sistent with the results for prespecified patient
populations in the individual studies. Prospective rando-
mised clinical trials are needed to evaluate the effects of
IL-6R inhibition on glycaemic indices, insulin sensitivity
and pancreatic β cell function in patients with comorbid
RA and diabetes and determine the clinical relevance of
differences in IL-6R, IL-1β and TNF inhibition.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-020-02229-5.
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